SOURCE: Pegasus Pharmaceuticals Inc.

October 30, 2006 09:30 ET

Pegasus/HeartView to Market Its HeartVue 6S Screening Device in Europe

PALM BEACH GARDENS, FL -- (MARKET WIRE) -- October 30, 2006 -- Pegasus/HeartView, LLC (PINKSHEETS: PGUZ) today announced that they are anticipating an EU CE Mark approval during November 2006 for their advanced screening technology, the HeartVue 6S System.

The CE (This stands for "Conformité Européene") Mark approval will authorize the Company to proceed with its marketing plans throughout the European Union. This approval signifies the quality and branding mark for products made or sold within the European Union. The CE Mark approval indicates to governments that the product can be legally sold within the European Union and the European Free Trade Association. It also indicates to customers that the product meets designated minimum safety standards. A distributor network will be set up involving many of the interested industry groups that viewed the system performing heart screening tests at the recent World Congress of Cardiology, September 2nd to 6th in Barcelona, Spain. Negotiations with potential distributors are ongoing from contacts made at this show and the American College of Cardiology's ACC 55th Scientific Session held in Atlanta, Georgia last March.

Pegasus/HeartView, LLC will be represented by Medical Computer Systems, one of the Company's OEM manufacturers at the upcoming Medica 2006 Show, the 38th International Trade Fair with the Congress World Forum For Medicine in Dusseldorf, Germany from November 15th - 18th, 2006. This benchmark event is the world's largest medical fair and is held in tandem with ComPaMed 2006 from November 15th - 17th, which is the 15th International Trade Fair for components, parts and raw materials for medical manufacturing at the Dusseldorf Trade Fair Center, Dusseldorf, Germany. The show will feature over 300 exhibitors, with a focus on cardiology, gastroenterology, oncology and imaging processes.

The HeartVue 6S System is an advanced, quick and accurate screening technology for early, non-invasive screening of heart disease. The technology uses only 4 limb wires (6 standard ECG leads) from the patient's wrists and ankles.

The device includes proprietary software that converts the electric conductivity of the cardiac tissue into a three dimensional color-coded visual picture, which is simple for physicians to interpret. The ECV device allows testers to observe the condition of the heart muscle, as well as the intensity of the heart stress load. It immediately provides a 3D visual of the patient's heart and an electrocardiogram, all in less than one minute.

HeartView, LLC, Cleveland, Ohio, holds the worldwide patent, manufacturing and marketing rights of the HeartVue 6S System. There is a patent pending for the device in the United States. For more information, please contact Paul Davey, Investor Services, at (778) 389-0915. Website: www.pegasusbiosciences.com . Email: paul@pegasusbiosciences.com, or Daniel P. Kesonen, Chairman & CEO of Pegasus Pharmaceuticals Inc., Palm Beach, Florida at (561) 626-9901.

Pegasus Pharmaceuticals adheres to the provisions, regulations and specifications of the Safe Harbor Act.

Contact Information